X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9253) 9253
Book Review (910) 910
Publication (394) 394
Newsletter (80) 80
Magazine Article (14) 14
Book Chapter (13) 13
Conference Proceeding (11) 11
Newspaper Article (7) 7
Trade Publication Article (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8509) 8509
humans (8052) 8052
cytarabine - administration & dosage (6511) 6511
male (5208) 5208
female (5158) 5158
antineoplastic combined chemotherapy protocols - therapeutic use (4275) 4275
middle aged (4226) 4226
adult (4048) 4048
oncology (3043) 3043
hematology (2901) 2901
aged (2884) 2884
adolescent (2360) 2360
leukemia, myeloid, acute - drug therapy (2218) 2218
remission induction (1926) 1926
chemotherapy (1816) 1816
cytarabine (1702) 1702
treatment outcome (1687) 1687
cytarabine - therapeutic use (1502) 1502
antineoplastic combined chemotherapy protocols - adverse effects (1439) 1439
daunorubicin - administration & dosage (1433) 1433
cytarabine - adverse effects (1432) 1432
etoposide - administration & dosage (1365) 1365
child (1322) 1322
antineoplastic combined chemotherapy protocols - administration & dosage (1302) 1302
methotrexate - administration & dosage (1235) 1235
cyclophosphamide - administration & dosage (1221) 1221
vincristine - administration & dosage (1220) 1220
cancer (1186) 1186
animals (1117) 1117
prognosis (1094) 1094
abridged index medicus (995) 995
combined modality therapy (979) 979
acute disease (968) 968
drug administration schedule (949) 949
child, preschool (921) 921
doxorubicin - administration & dosage (909) 909
therapy (907) 907
disease-free survival (899) 899
acute myelogenous leukemia (890) 890
leukemia (820) 820
recurrence (818) 818
survival rate (771) 771
acute myeloid-leukemia (760) 760
acute myeloid leukemia (744) 744
prednisone - administration & dosage (729) 729
cytarabine - pharmacology (712) 712
time factors (707) 707
survival analysis (684) 684
dose-response relationship, drug (681) 681
mice (672) 672
retrospective studies (661) 661
aged, 80 and over (652) 652
leukemia, myeloid - drug therapy (649) 649
transplantation (645) 645
antineoplastic agents - administration & dosage (640) 640
leukemia, myeloid, acute - mortality (626) 626
mitoxantrone - administration & dosage (622) 622
leukemia - drug therapy (618) 618
follow-up studies (617) 617
idarubicin - administration & dosage (599) 599
infant (596) 596
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (582) 582
drug therapy, combination (579) 579
young adult (573) 573
antineoplastic agents - therapeutic use (537) 537
cytosine-arabinoside (514) 514
antimetabolites, antineoplastic - administration & dosage (506) 506
bone marrow transplantation (488) 488
dexamethasone - administration & dosage (481) 481
care and treatment (471) 471
thioguanine - administration & dosage (465) 465
hematopoietic stem cell transplantation (459) 459
lymphoma, non-hodgkin - drug therapy (450) 450
leukemia, myeloid, acute - pathology (447) 447
medicine & public health (447) 447
pharmacology & pharmacy (446) 446
transplantation, autologous (444) 444
survival (436) 436
aml (435) 435
mercaptopurine - administration & dosage (434) 434
salvage therapy (432) 432
risk factors (422) 422
research (413) 413
dosage and administration (403) 403
cisplatin - administration & dosage (401) 401
children (394) 394
prospective studies (391) 391
prednisolone - administration & dosage (390) 390
bone-marrow transplantation (364) 364
clinical trials as topic (357) 357
leukemia, myeloid, acute - therapy (355) 355
stem cells (354) 354
trial (354) 354
acute lymphoblastic-leukemia (353) 353
age factors (352) 352
carmustine - administration & dosage (350) 350
leukemia, myeloid, acute - genetics (345) 345
injections, spinal (343) 343
pediatrics (342) 342
asparaginase - administration & dosage (341) 341
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8260) 8260
Japanese (497) 497
German (115) 115
Chinese (97) 97
French (90) 90
Spanish (87) 87
Polish (73) 73
Russian (70) 70
Italian (20) 20
Czech (15) 15
Hungarian (12) 12
Danish (6) 6
Portuguese (6) 6
Hebrew (3) 3
Dutch (2) 2
Norwegian (2) 2
Serbian (2) 2
Slovak (2) 2
Croatian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 01/2013, Volume 121, Issue 1, pp. 48 - 53
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
British journal of cancer, ISSN 0007-0920, 2014, Volume 111, Issue 6, pp. 1072 - 1079
Background: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy... 
cytarabine | INTERMEDIATE-GRADE | FOLLOW-UP | diffuse large B-cell lymphoma | methotrexate intrathecal | CHEMOTHERAPY | central nervous system | RELAPSE | central nervous system prophylaxis | ONCOLOGY | STANDARD CHOP | NON-HODGKINS-LYMPHOMA | CNS PROPHYLAXIS | AGGRESSIVE LYMPHOMA | RITUXIMAB ERA | ELDERLY-PATIENTS | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Central Nervous System Neoplasms - secondary | Young Adult | Central Nervous System Neoplasms - prevention & control | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Doxorubicin - administration & dosage | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Rituximab | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Administration, Intravenous | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Aged | Index Medicus | intrathecal | methotrexate | Clinical Study
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1214 - 1221
From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n... 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
Durable remissions and long‐term survival can be achieved with a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome‐positive... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IDARUBICIN | THERAPY | DOSE ARA-C | PEDIATRIC-PATIENTS | SENSITIVITY | RISK | CHILDHOOD LEUKEMIA | EXPERIENCE | ACCELERATED APPROVAL | ONCOLOGY GROUP | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Cytogenetics | Cancer therapies | Data bases | Cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Cancer, ISSN 0008-543X, 12/2014, Volume 120, Issue 23, pp. 3660 - 3668
Retrospective analysis indicates that pediatric‐based therapy for acute lymphoblastic leukemia is superior to adult‐type therapy. This single institution... 
augmented Berlin‐Frankfurt‐Münster | pediatric‐based therapy | Philadelphia chromosome‐negative ALL | acute lymphoblastic leukemia | pediatric‐based regimens | Augmented Berlin-Frankfurt-Munster | Pediatric-based regimens | Acute lymphoblastic leukemia | Pediatric-based therapy | Philadelphia chromosome-negative ALL | ASPARAGINASE | pediatric-based therapy | pediatric-based regimens | PROGNOSTIC-FACTORS | PROTOCOLS | ACUTE LYMPHOCYTIC-LEUKEMIA | augmented Berlin-Frankfurt-Munster | RISK | INDUCTION | CANCER GROUP | CHILDHOOD | CHILDRENS ONCOLOGY GROUP | ONCOLOGY | MINIMAL RESIDUAL DISEASE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Induction Chemotherapy | Male | Consolidation Chemotherapy | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Female | Maintenance Chemotherapy | Daunorubicin - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Cohort Studies | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
Journal Article